The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015.

Bayer, coveting top spots in animal and consumer health, may eye deals for Zoetis, Pfizer OTC

Bayer may have a big-time move up its sleeve, Reuters ' sources say--and it could include animal health leader Zoetis or Pfizer's consumer offerings.

Remicade biosim may face an uphill battle with U.S. docs, analyst says

Remsima, a biosimilar of Johnson & Johnson's Remicade from Pfizer's Hospira and partner Celltrion, is tearing it up in Europe. But don't expect things to play out the same way in the U.S., a Bernstein analyst says.

Icahn: Change the international tax code, and Pfizer will drop its 'travesty' of a merger

The tax benefits of buying Allergan are Pfizer's No. 1 reason for doing the $160 billion deal. In fact, some analysts see the $2 billion in potential tax savings as the merger's only substantial advantage.

Cheaper Chinese pills could threaten Viagra and Cialis market share

Cheaper Chinese versions of erectile dysfunction (ED) treatments Viagra and Cialis are threatening to eat into the market share of the Western-made drugs as some of the 127 million Chinese men suffering from ED turn to domestic alternatives.

Pfizer nabs speedy FDA review for new use of lung cancer med Xalkori

Pfizer's Xalkori is already used to treat patients with metastatic non-small cell lung cancer whose tumors are ALK-positive. But now it's on its way to snagging a speedy nod in another group of NSCLC patients, too.

Pfizer's Ibrance pricing shows multiyear market analysis the source of some high costs

The industry often points to the high cost of R&D for new lifesaving drugs as the main factor behind prices, but a deep dive by the Wall Street Journal into Pfizer's pricing on breast cancer drug Ibrance finds that some drugmakers instead rely on multiyear, complex market analysis to find a price point the market will bear.

Cellectis suffers worst day in two years after Pfizer event disappoints investors

Cellectis suffered its worst day in two years on the Paris stock exchange on Monday. The 13% slump began when it became clear that a conference call held by Cellectis, Pfizer and Servier would do little more than clarify the roles of each party in their recently struck CAR-T collaboration.

With Paris spotlight on climate change, here's how Big Pharma stacks up

While pharma may not have the carbon footprint of energy or heavy manufacturing, it has other connections to environment and climate issues. The way climate change will affect public health, for instance, is a growing topic in global "green" pharma discussions, as is prescription drug pollution in the environment.

Pfizer bets up to $1B on BioAtla's approach to immuno-oncology

San Diego biotech BioAtla is sharing its immuno-oncology assets with Pfizer in a deal worth up to $1 billion, mixing and matching technologies in hopes of hitting on a winning combination.